Satellos Bioscience
CompanyCanada
Satellos Bioscience develops one asset, in phase 2 (forazapadin in Duchenne muscular dystrophy). Mostly small molecule acting on stem cell maintenance and AAK1; based in Canada.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- US$58.4m
- 1
- Trial
- 1
- Signal
Pipeline
1Inhibits AAK1 to restore muscle stem cell asymmetric division and promote muscle regeneration.
Phase 2, Small molecule, Stem cell maintenance, AAK1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Funding rounds and grants3
- People24
- Signals1
- Similar companies6